Combined activity of COX-1 and COX-2 is increased in non-neoplastic colonic mucosa from colorectal neoplasia patients

Table 1 Drug-induced changes in short circuit current (SCC)

	CRN-pts Mean ΔSCC, SEM (μA·cm^− 2)	CRN-pts N/n	Ctrls Mean ΔSCC, SEM (μA·cm^− 2)	Ctrls N/n	p-value
Baseline SCC	91 ± 10.1	22/42	95 ± 26.6	21/30	0.518
Amiloride	−77 ± 13.4	17/38	−30 ± 15.1	13/22	0.006 *
Theophylline	73.5 ± 7.1	17/38	50.5 ± 6.9	13/22	0.025 *
SC-560 + Celecoxib	−66.7 ± 3.5	17/38	−54.7 ± 4.3	13/22	0.036 *
PGE₂	87.5 ± 32.3	15/26	73.0 ± 17.3	10/19	0.275
Bumetanide	−41.5 ± 5.3	15/32	−55.0 ± 9.4	7/18	0.261
Ouabain	−70.5 ± 14.4	13/24	−93.0 ± 14.7	7/18	0.431

Baseline SCCs are absolute values, while amiloride (20 μM, apical), theophylline (400 μM, both sides), SC-560 + Celecoxib (500 μM, both sides), prostaglandin (PGE₂) (100 nM, serosal), bumetanide (13 μM, serosal) and ouabain (200 μM, serosal) effects are changes from prestimulatory SCC (ΔSCC). SC-560 and Celecoxib are selective COX-1 and COX-2 inhibitors. SC-560 + Celecoxib represent the combined SCC inhibition data of both COX-1/indomethacin and COX-2/indomethacin application. CRN-pts values represent SCC or ΔSCC in biopsies from colorectal neoplasia patients and ctrls values are for patients without colorectal neoplasia. N = number of patients, n = number of biopsies, in parenthesis (N/n). * p-value < 0.05